Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Oxaliplatin Sensitizes OS Cells to TRAIL-induced Apoptosis Via Down-regulation of Mcl1

  • Huang, Tao (Department of Orthopedics, The First Affiliated Hospital of China Medical University) ;
  • Gong, Wei-Hua (Beth Israel Deaconess Medical Center, Harvard Medical School) ;
  • Li, Xiu-Cheng (Department of Orthopedics, The First Affiliated Hospital of China Medical University) ;
  • Zou, Chun-Ping (Department of Orthopedics, The First Affiliated Hospital of China Medical University) ;
  • Jiang, Guang-Jian (Beth Israel Deaconess Medical Center, Harvard Medical School) ;
  • Li, Xu-Hui (Beth Israel Deaconess Medical Center, Harvard Medical School) ;
  • Qian, Hao (Department of Orthopedics, The First Affiliated Hospital of China Medical University)
  • Published : 2012.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To investigate the killing effect on OS cells of a combination of oxaliplatin and TRAIL and related molecular mechanisms. Methods: TRAIL and oxaliplatin were applied to OS732 cells singly or jointly and survival inhibition rates were measured by MTT assay, changes of cellular shape being assessed with inverted phase contrast and fluorescence microscopy. Apoptotic rates were analyzed by flow cytometry (FCM) and immunocytochemistry was used to examine Mcl1 expression of OS732 cells. Results: The survival inhibition rate of combined application of $100{\mu}g/ml$ TRAIL and $1{\mu}g/ml$ oxaliplatin on OS-732 cells was significantly higher than that of either agent singly (p<0.01). Changes of cellular shape and apoptotic rates also indicated apoptosis-inducing effects of combined application to be much stronger than those of individual application. Oxaliplatin had the effect of down-regulating Mcl1 expression and sensitizing OS cells to TRAIL-induced apoptosis. Conclusion: A combination of TRAIL and oxaliplatin exerts strong killing effects on OS-732 cells which might be related to down-regulation of Mcl1 expression.

Keywords

References

  1. Arlt MJ, Walters DK, Banke IJ, et al (2011). The antineoplastic antibiotic taurolidine promotes lung and liver metastasis in two syngeneic osteosarcoma mouse models and exhibits severe liver toxicity. Int J Cancer, 131, E804-12.
  2. Beaty O, 3rd Berg S, Blaney S, et al (2010). A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer, 55, 440-5. https://doi.org/10.1002/pbc.22544
  3. Bouralexis S, Findlay DM, Atkins GJ, et al (2003). Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer, 89, 206-14. https://doi.org/10.1038/sj.bjc.6601021
  4. Bruland OS, and Pihl A (1997). On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 33, 1725-31. https://doi.org/10.1016/S0959-8049(97)00252-9
  5. Brunat-Mentigny, M., and Kohler, R. (1993). [Osteosarcoma]. Rev Prat, 43, 2197-203.
  6. Clairambault J, Claude D, Filipski E, Granda T, Levi F (2003). [Toxicity and anti-tumour efficacy of oxaliplatin on Glasgow osteosarcoma induced in mice: a mathematical model]. Pathol Biol (Paris), 51, 212-5. https://doi.org/10.1016/S0369-8114(03)00045-2
  7. El Fajoui Z, Toscano F, Jacquemin G et al (2011). Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. Gastroenterology, 141, 663-73. https://doi.org/10.1053/j.gastro.2011.04.055
  8. Geoerger B, Doz F, Gentet JC et al (2008). Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. J Clin Oncol, 26, 4394-400. https://doi.org/10.1200/JCO.2008.16.7585
  9. Gores GJ, Kaufmann SH (2012). Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev, 26, 305-11. https://doi.org/10.1101/gad.186189.111
  10. Hartmann C, Weinel P, Schmid H, et al (2011). Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children. J Pediatr Hematol Oncol, 33, 344-349. https://doi.org/10.1097/MPH.0b013e31820994ec
  11. Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA (2010). Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem, 285, 19162-72. https://doi.org/10.1074/jbc.M109.091645
  12. Kim J H, Park B, Gupta SC, et al (2012). Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway. Antioxid Redox Signal, 16, 413-27. https://doi.org/10.1089/ars.2011.3982
  13. Kubista B, Erovic BM, Klinger H, Sulzbacher I, Trieb K (2004). CD9 expression is not a prognostic factor in human osteosarcoma. Cancer Lett, 209, 105-10. https://doi.org/10.1016/j.canlet.2003.11.038
  14. Lin F, Wang Q, Yu W et al (2011). Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol, 7, 270-5. https://doi.org/10.1111/j.1743-7563.2011.01406.x
  15. Locklin RM, Federici E, Espina B, et al (2007). Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther, 6, 3219-28. https://doi.org/10.1158/1535-7163.MCT-07-0275
  16. Moon MH, Jeong JK, Seo JS, et al (2011). Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation. Exp Mol Med, 43, 138-145. https://doi.org/10.3858/emm.2011.43.3.016
  17. Pritchard DM, Berry D, Przemeck SM, et al (2008). Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. Am J Physiol Gastrointest Liver Physiol, 295, G798-805. https://doi.org/10.1152/ajpgi.00015.2008
  18. Rassidakis GZ, Lai R, McDonnell TJ, et al (2002). Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. Am J Pathol 160, 2309-10. https://doi.org/10.1016/S0002-9440(10)61178-9
  19. Rizza SA, Challagundla KB, Natesampillai S, et al (2011). TRAIL dependent fratricidal killing of gp120 primed hepatocytes by HCV core expressing hepatocytes. PLoS One, 6, e27171. https://doi.org/10.1371/journal.pone.0027171
  20. Seol DW (2011). p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun, 416, 222-5. https://doi.org/10.1016/j.bbrc.2011.11.053
  21. Song S, Choi K, Ryu, SW, Kang SW, Choi C (2011). TRAIL promotes caspase-dependent pro-inflammatory responses via PKCdelta activation by vascular smooth muscle cells. Cell Death Dis, 2, e223. https://doi.org/10.1038/cddis.2011.103
  22. Takeda S, Iwai A, Nakashima M, et al (2007). LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma. Anticancer Res, 27, 761-8.
  23. Trieb K, Kotz R (2001). Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol, 33, 11-7. https://doi.org/10.1016/S1357-2725(00)00066-2
  24. Van Valen F, Fulda S, Schafer KL, et al (2003). Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer, 107, 929-40. https://doi.org/10.1002/ijc.11503
  25. Wiley SR, Schooley K, Smolak PJ, et al (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673-82. https://doi.org/10.1016/1074-7613(95)90057-8
  26. Yuan JM, Li XD, Liu ZY, et al (2011). Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells. Asian Pac J Cancer Prev, 12, 3465-9.
  27. Zhang G, Li M, Jin J, Bai Y, Yang C (2011). Knockdown of S100A4 decreases tumorigenesis and metastasis in osteosarcoma cells by repression of matrix metalloproteinase-9. Asian Pac J Cancer Prev, 12, 2075-80.
  28. Zhou W, Hu J, Tang H, et al (2011). Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors. BMC Cancer, 11, 485. https://doi.org/10.1186/1471-2407-11-485

Cited by

  1. Dealing Naturally with Stumbling Blocks on Highways and Byways of TRAIL Induced Signaling vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8041
  2. Drugs from Marine Sources: Modulation of TRAIL Induced Apoptosis in Cancer Cells vol.15, pp.20, 2014, https://doi.org/10.7314/APJCP.2014.15.20.9045
  3. Neuroprotective activities of curcumin and quercetin with potential relevance to mitochondrial dysfunction induced by oxaliplatin vol.253, pp.2, 2016, https://doi.org/10.1007/s00709-015-0821-6
  4. MicroRNA-302b Enhances the Sensitivity of Hepatocellular Carcinoma Cell Lines to 5-FU via Targeting Mcl-1 and DPYD vol.16, pp.10, 2015, https://doi.org/10.3390/ijms161023668